Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.
The combination brings together the commercial portfolios of Paratek, including NUZYRA® and XHANCE®, and Radius, including TYMLOS®, to create a diversified specialty pharmaceutical portfolio expected to generate nearly $1 billion in annual revenue in 2026, while further advancing Paratek's and B‑FLEXION's strategy of building an integrated pharmaceutical platform focused on high‑need, targeted therapeutic areas.
The Mintz team was led by Richard Gervase, Member and Chair of the firm's Royalty & Revenue Interest Financing Transactions Group, with support from Tali Tuchin (Corporate), Eric Blythe (Bankruptcy & Restructuring), Joanne Hawana (Regulatory), and Associates Peter Hecker (Intellectual Property), Christine Pemberton (Intellectual Property), and Joshua Li (Intellectual Property)
Read Sixth Street's press release here, Blackstone's press release here, and Paratek's press release here.